rs768372697
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 7P and 1B. PM2PP3_StrongPP5BS1_Supporting
The NM_013339.4(ALG6):c.338G>A(p.Arg113His) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000527 in 1,613,080 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_013339.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALG6 | NM_013339.4 | c.338G>A | p.Arg113His | missense_variant | 5/15 | ENST00000263440.6 | NP_037471.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALG6 | ENST00000263440.6 | c.338G>A | p.Arg113His | missense_variant | 5/15 | 5 | NM_013339.4 | ENSP00000263440 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152130Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 250898Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135568
GnomAD4 exome AF: 0.0000507 AC: 74AN: 1460950Hom.: 0 Cov.: 30 AF XY: 0.0000495 AC XY: 36AN XY: 726836
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152130Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74304
ClinVar
Submissions by phenotype
ALG6-congenital disorder of glycosylation 1C Pathogenic:2Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | May 09, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 28, 2024 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 17, 2023 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 113 of the ALG6 protein (p.Arg113His). This variant is present in population databases (rs768372697, gnomAD 0.02%). This missense change has been observed in individual(s) with congenital disorder of glycosylation type 1c (PMID: 16321363). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 551854). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ALG6 protein function with a positive predictive value of 80%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on ALG6 function (PMID: 16321363). This variant disrupts the p.Arg113 amino acid residue in ALG6. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 31117816). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 08, 2022 | Variant summary: ALG6 c.338G>A (p.Arg113His) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 250898 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.338G>A has been reported in the literature as a bialelic compound heterozygous genotype in at-least one individual affected with clinically and biochemically diagnosed Congenital Disorder Of Glycosylation Type 1C (Eklund_2006). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 classifying it as pathogenic (n=1) and VUS (n=1).Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at